Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Abstract 3405: Targeting HGF-mediated resistance to vemurafenib in V600E BRAF mutant melanoma cell lines.

(2014) Sean Caenepeel et al.   CANCER RESEARCH

Abstract 2078: Synergistic effects of c-Met and BRAF inhibitors and role of c-Met as a therapeutic target in human melanoma.

(2014) Deven Etnyre et al.   CANCER RESEARCH

Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor

(2014) Takayuki Nakagawa et al.   CANCER SCIENCE

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors

(2014) Cecilia Lezcano et al.   MODERN PATHOLOGY

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment

(2014) Leonard Appleman et al.   OncoTargets and Therapy

Targeting MET: why, where and how?

(2013) Elena Ghiso et al.   CURRENT OPINION IN PHARMACOLOGY

Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress

(2013) J. Jean Cui   JOURNAL OF MEDICINAL CHEMISTRY

HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

(2013) E. Penuel et al.   MOLECULAR CANCER THERAPEUTICS

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

The mesenchyme in malignancy: A partner in the initiation, progression and dissemination of cancer

(2012) Mark A. Glaire et al.   PHARMACOLOGY & THERAPEUTICS

Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma

(2012) Brian J. Nickoloff et al.   Pigment Cell & Melanoma Research